Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non Operating Income (2016 - 2025)

Fennec Pharmaceuticals' Other Non Operating Income history spans 15 years, with the latest figure at -$2.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 7488.89% year-over-year to -$2.0 million, compared with a TTM value of -$2.0 million through Dec 2025, down 2365.85%, and an annual FY2025 reading of -$2.0 million, down 2365.85% over the prior year.
  • Other Non Operating Income for Q4 2025 was -$2.0 million at Fennec Pharmaceuticals, down from -$3000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $17000.0 in Q2 2025, with the low at -$2.0 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$124294.1, with a median of -$3000.0 recorded in 2022.
  • Year-over-year, Other Non Operating Income surged 400.0% in 2023 and then crashed 7488.89% in 2025.
  • Tracing FENC's Other Non Operating Income over 5 years: stood at -$1000.0 in 2021, then tumbled by 200.0% to -$3000.0 in 2022, then skyrocketed by 166.67% to $2000.0 in 2023, then crashed by 1450.0% to -$27000.0 in 2024, then crashed by 7488.89% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Other Non Operating Income are -$2.0 million (Q4 2025), -$3000.0 (Q3 2025), and $17000.0 (Q2 2025).